Neulastim

DRUG2 trials

Sponsors

Eurofarma Laboratorios S.A., Nanogen Pharmaceutical Biotechnology Joint Stock Company

Conditions

Breast CancerBreast Cancer Female

Phase 3

Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy

WithdrawnNCT02768714

Eurofarma Laboratorios S.A.Breast Cancer

Start: 2018-01-31End: 2019-10-31Updated: 2017-09-15

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

CompletedNCT03381417

Nanogen Pharmaceutical Biotechnology Joint Stock CompanyBreast Cancer Female

Start: 2016-10-06End: 2017-11-06Updated: 2018-01-02